García RJ, Parra RJA, Márquez SM, López AG

Language: Spanish
References: 11
Page: 107-112
PDF size: 301.39 Kb.

ABSTRACT

Background: Patients with chronic kidney disease are at high cardiovascular risk, with some risk factors related conditions co-morbidities, renal damage or dialysis. Particularly cardiovascular mortality in nephropathy patients undergoing peritoneal dialysis, suggesting the involvement of this therapy as a risk factor, especially when associated with left ventricular hypertrophy is not adaptive.
Methods: For cardiovascular risk during a peritoneal dialysis program in patients with chronic renal failure we designed a cross sectional study, comparative study that included patients managed replacement of renal function by intermittent peritoneal dialysis was admitted to internal medicine Balbuena. Cardiovascular risk was estimated by electrocardiographic evidence of left ventricular hypertrophy, hypercholesterolemia and presence through laboratory analysis.
Results: We studied 42 patients with mean age 52.5 ± 11 years. The only significant cardiovascular risk factor was the time management dialysis ≥ 6 months (odds ratio (OR) = 20.1, 95% CI 2.29-176, p = 0.02 for LVH, and 2.8, 95% CI 0.78-9.9, p = 0.13 for hypercholesterolemia), while managing continuous dialysis was not associated with increased cardiovascular risk (OR = 0.61, 95% CI 0.15-2.47, p = 0.73 for LVH, and OR = 1.43 95% CI 0.4-5.0, p = 0.8 for hypercholesterolemia).
Conclusions: Regular intermittent peritoneal dialysis in itself is not clearly associated with increased cardiovascular risk, whereas the irregular handling time dialysis and / or the presence of peritoneal infection appear to be associated with cardiovascular risk factors.

REFERENCES

1. Gérard M. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. The Clinical Epidemiology of Cardiovascular Diseases in Chronic Kidney Disease. Seminars in Dialysis 2003;16(2):85-94.

2. Bruce F, Hemmelgarn C and B R. Is chronic kidney disease a cardiovascular disease risk factor? The Clinical Epidemiology of Cardiovascular Diseases in Chronic Kidney Disease. Seminars in Dialysis 2003;16(2):95-100.

3. Guadalajara-Boo JF. Entendiendo la hipertrofia ventricular izquierda. Arch Cardiol Mex 2007;77:175-180.

4. Kerstin A, et al. Left ventricular hypertrophy in renal failure. Kidney International 1998;54(Suppl 68):S-78-S-85.

5. Adeera L. Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney International 2002;61(Suppl 80):S35-S38.

6. Tucker B, et al. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 1997;12:724-728.

7. Chan ChT, et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney International 2002;61:2235-2239.

8. London GM, et al. Alterations of Left Ventricular Hypertrophy in and Survival of Patients Receiving Hemodialysis: Follow-up of an Interventional Study. J Am Soc Nephrol 2001;12: 2759-2767.

9. Goldstein S, et al. Echocardiographic Diagnosis of Left Ventricular Hypertrophy. Circulation 1978;57;1140-1144.

10. Dangri P, et al. Echocardiographic assessment of left ventricular hypertrophy in patients of chronic renal failure. Indian J Nephrol 2003;13:92-97.